{
    "clinical_study": {
        "@rank": "112755", 
        "arm_group": [
            {
                "arm_group_label": "2 times 1", 
                "arm_group_type": "Other", 
                "description": "PVI will be performed using a cryoballoon ablation application time of 2 times 1 minute"
            }, 
            {
                "arm_group_label": "2 times 2", 
                "arm_group_type": "Other", 
                "description": "PVI will be performed using a cryoballoon ablation application time of 2 times 2 minutes"
            }, 
            {
                "arm_group_label": "2 times 3", 
                "arm_group_type": "Other", 
                "description": "PVI will be performed using a cryoballoon ablation application time of 2 times 3 minutes"
            }
        ], 
        "brief_summary": {
            "textblock": "Cryoballoon based therapy is an established therapy for the treatment of (paroxysmal) atrial\n      fibrillation. However, with the rapid evolution in cryoablation technique and its increased\n      effectiveness, the risk of complications increases. Therefore it is of utmost importance to\n      define the optimal duration of cryoballoon ablation time.The objective of the study is \tto\n      assess the optimal ablation duration using the second generation cryoballoon for isolation\n      of pulmonary veins in the treatment of atrial fibrillation."
        }, 
        "brief_title": "Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "detailed_description": {
            "textblock": "Rationale Cryoballoon based therapy is an established therapy for the treatment of\n      (paroxysmal) atrial fibrillation. However, with the rapid evolution in cryoablation\n      technique and its increased effectiveness, the risk of complications increases. Therefore it\n      is of utmost importance to define the optimal duration of cryoballoon ablation time.\n\n      Objective To assess the optimal ablation duration using the second generation cryoballoon\n      for isolation of pulmonary veins in the treatment of atrial fibrillation.\n\n      Study design The study is designed as a prospective multicentre randomized efficacy study.\n\n      Study population Patients 18-70 years of age with paroxysmal atrial fibrillation eligible\n      for pulmonary vein isolation according to current international guidelines.\n\n      Intervention Patients will be randomized to 2 cycles of 1, 2 or 3 minutes of cryoballoon\n      ablation after reaching the temperature \"plateau phase\".\n\n      Main study parameters/endpoints Acute success of pulmonary vein isolation.\n\n      Nature and extent of the burden and risks associated with participation, benefit and group\n      relatedness:\n\n      No additional risk is present as the procedure is common clinical practice, current\n      cryoballoon application time is 3 minutes Shorter application times are not expected to add\n      to the risk."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Paroxysmal atrial fibrillation for which \u2265 1 electrical and/or chemical\n             cardioversions eligible for pulmonary vein isolation according to current\n             international guidelines.\n\n          -  Age < 70 years.\n\n          -  Willing and able to sign informed consent.\n\n          -  Willing to and capable of following the requested study procedures.\n\n        Exclusion Criteria:\n\n          -  Age < 18 years.\n\n          -  Pregnancy\n\n          -  Life or follow-up expectancy < 12 months.\n\n          -  Previous PVI.\n\n          -  Contrast allergy.\n\n          -  Creatin clearance level < 60.\n\n          -  Left ventricular ejection fraction < 40%\n\n          -  Abnormal left atrium anatomy defined as number of PV's \u2260 4 or Left Atrium diameter\n             >50mm (measured in the parasternal long axis, as assessed with transthoracic\n             echocardiography). This will lead to exclusion after inclusion but before\n             randomisation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "222", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074566", 
            "org_study_id": "NL47337.044.13"
        }, 
        "intervention": {
            "arm_group_label": [
                "2 times 1", 
                "2 times 2", 
                "2 times 3"
            ], 
            "description": "PVI using cryoballoon", 
            "intervention_name": "Cryoballoon ablation", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pulmonary Vein Isolation", 
            "Atrial fibrillation", 
            "Cryoballoon therapy", 
            "Duration"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": [
            {
                "contact": {
                    "email": "cre@mst.nl", 
                    "last_name": "Department of Cardioresearch", 
                    "phone": "+31534873011"
                }, 
                "facility": {
                    "address": {
                        "city": "Enschede", 
                        "country": "Netherlands", 
                        "state": "Nederland", 
                        "zip": "7500 KA"
                    }, 
                    "name": "Medisch Spectrum Twente"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "trang.dinh@mumc.nl", 
                    "last_name": "Trang Dinh", 
                    "phone": "+31433877095"
                }, 
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6229 HX"
                    }, 
                    "name": "Maastricht University Medical Centre"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Prospective Randomized Multicentre Efficacy Study on Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Netherlands: Medische Ethische Toetsingscommissie Twente", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of successfull pulmonary vein isolation after 2 x 1/2/3 minutes of cryoballoon application. The assessment of this outcome will take place during the procedure.", 
            "measure": "Number of patients wit successfull pulmonary vein isolation", 
            "safety_issue": "No", 
            "time_frame": "up to 6 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074566"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Thorax Centrum Twente", 
            "investigator_full_name": "Harald Verheij", 
            "investigator_title": "Drs.", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Complications being:\nPhrenic nerve palsy or diminishment of diaphragm excursion during cryo-ablation.\nTemperatures reaching <12 C in the oesophagus during cryoablation.\nOther complications such as delayed gastric emptying, pericardial fluid/tamponade, haemoptoe, vascular complications.", 
                "measure": "Number of complications", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "The assessment of this outcome will take place during the procedure", 
                "measure": "Patients in which acute success of pulmonary vein isolation (after 1 freezing cycle) was present", 
                "safety_issue": "No", 
                "time_frame": "up to 6 minutes"
            }, 
            {
                "description": "The assessment of this outcome will take place during the procedure.", 
                "measure": "Duration of thaw phase (= time between end of freezing to automatic deflation of the balloon) related to acute success of pulmonary vein isolation", 
                "safety_issue": "No", 
                "time_frame": "up to 6 minutes"
            }, 
            {
                "description": "The assessment of this outcome will take place right after the procedure. It measures procedural parameters.", 
                "measure": "Procedure time, fluoroscopy time, amount of contrast used", 
                "safety_issue": "No", 
                "time_frame": "up to 6 minutes"
            }, 
            {
                "description": "The measurement will take place during the procedure. It registrates the lower esophageal temperature ande the development during the course of the procedure.", 
                "measure": "Lower Esophageal Temperature development", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 minutes"
            }, 
            {
                "measure": "Atrial Fibrillation recurrence", 
                "safety_issue": "No", 
                "time_frame": "after 1 year follow up"
            }, 
            {
                "measure": "Balloon temperatures measured by the console", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 minutes"
            }
        ], 
        "source": "Thorax Centrum Twente", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Thorax Centrum Twente", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Academisch Ziekenhuis Maastricht", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Harald Verheij", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}